A Randomized, Double-Blind, Placebo Controlled, Multicenter Phase 2a Study to Assess Safety, Daily Respiratory Symptoms, Pharmacokinetics, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Multicenter Phase 2a Study to Assess Safety, Daily Respiratory Symptoms, Pharmacokinetics, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs YPL 001 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Yungjin Pharm Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
    • 29 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top